Boston Scientific heads into its July 29 earnings report with analysts uniformly bullish but equally unanimous in cutting their expectations — a disconnect that puts the quality of the actual numbers front and center.
The analyst story is the dominant pre-print narrative. Every recent change has been a target reduction, with no rating downgrades attached. Truist, Mizuho, RBC Capital, Needham, Evercore, Stifel, and Jefferies all trimmed targets over the past six weeks, with cuts ranging from modest to severe — Mizuho went from $90 to $70, Jefferies from $100 to $67. The mean target now sits at $72.43, well above the current price of $44.25, which on the surface implies significant upside. The gap is wide enough to warrant caution: this consensus reflects pre-reset targets and may not yet fully reflect the trajectory of the cuts. Every firm has kept Buy or Outperform ratings intact, signalling that the Street sees the valuation as compelling even after the markdown — but the direction of travel has been consistently negative heading into the print.
The bull and bear cases center on the same product lines but reach different conclusions. Bulls point to the global atrial fibrillation market, which Boston Scientific expects to expand from $9 billion to $15 billion by 2028, and to strong survey data suggesting healthcare professionals anticipate an 18% volume increase in related procedures. Bears counter that radiofrequency ablation share is projected to slide from 34% to 23% by 2030, and that the cryoablation segment faces similar erosion, with pricing pressure and rising debt compounding the headwinds. The factor scores add texture: the analyst recommendation differential ranks in the 95th percentile of the universe — meaning the consensus skew toward Buy is unusually strong — yet the 12-month forward EPS growth rank sits in just the 21st percentile, reflecting muted near-term earnings momentum.
Short interest tells a notably calm story. At 1.9% of free float and down nearly 48% over the past month — driven by a sharp step-down in mid-to-late June — bears have been covering, not building. Borrowing costs are negligible at 0.30%, and availability is vast, with shares to borrow running at roughly 89 times current short interest. There is no lending-market pressure of any kind. Options positioning is equally subdued: the put/call ratio of 0.39 is only marginally above its 20-day average of 0.37, a z-score of 0.68 that reflects near-normal sentiment rather than any rush to hedge. The stock is down 3% over the past month at $44.25, though it has stabilised with a flat week.
Insider activity from May adds one more data point worth noting. Three directors — including Lead Independent Director Edward Ludwig — made open-market purchases around $56 to $57 per share in late May, collectively putting roughly $550,000 to work. The stock has since fallen a further 20% below those levels, meaning the directors who bought are sitting on losses. Whether that signals conviction at current prices or reflects information that predated a deteriorating outlook is precisely what Tuesday's print will resolve.
The earnings report is therefore less about whether Boston Scientific is growing and more about whether management can demonstrate that the AFib and interventional cardiology pipeline justifies a stock trading nearly 50% below its 52-week high — and why the Street's target-cutting cycle should stop here.
See the live data behind this article on ORTEX.
Open BSX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
